ResMed Inc. (NYSE:RMD) Stock Holdings Trimmed by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC trimmed its holdings in shares of ResMed Inc. (NYSE:RMD - Free Report) by 17.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,705 shares of the medical equipment provider's stock after selling 5,785 shares during the period. O Shaughnessy Asset Management LLC's holdings in ResMed were worth $6,107,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Mawer Investment Management Ltd. lifted its holdings in shares of ResMed by 14.2% during the 4th quarter. Mawer Investment Management Ltd. now owns 87,443 shares of the medical equipment provider's stock valued at $19,997,000 after acquiring an additional 10,889 shares in the last quarter. Schroder Investment Management Group lifted its stake in shares of ResMed by 59.0% during the fourth quarter. Schroder Investment Management Group now owns 94,088 shares of the medical equipment provider's stock worth $21,593,000 after purchasing an additional 34,924 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of ResMed by 9.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 216,127 shares of the medical equipment provider's stock worth $49,426,000 after buying an additional 17,951 shares during the period. Allianz SE purchased a new stake in shares of ResMed in the fourth quarter worth about $373,000. Finally, Intrust Bank NA raised its holdings in shares of ResMed by 2.3% during the 4th quarter. Intrust Bank NA now owns 5,500 shares of the medical equipment provider's stock valued at $1,258,000 after buying an additional 122 shares during the period. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $227.71, for a total value of $455,420.00. Following the sale, the director now directly owns 75,218 shares of the company's stock, valued at $17,127,890.78. This trade represents a 2.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kaushik Ghoshal sold 9,745 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $239.31, for a total transaction of $2,332,075.95. Following the transaction, the insider now directly owns 9,725 shares of the company's stock, valued at approximately $2,327,289.75. This trade represents a 50.05 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,004 shares of company stock worth $9,178,648 over the last ninety days. Company insiders own 0.71% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on RMD shares. Needham & Company LLC restated a "hold" rating on shares of ResMed in a report on Friday, January 31st. StockNews.com lowered shares of ResMed from a "buy" rating to a "hold" rating in a report on Wednesday. Morgan Stanley started coverage on shares of ResMed in a research note on Wednesday, March 19th. They set an "overweight" rating and a $280.00 price target on the stock. Citigroup upgraded ResMed from a "neutral" rating to a "buy" rating in a research note on Wednesday, March 5th. Finally, KeyCorp boosted their price target on ResMed from $266.00 to $280.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. One research analyst has rated the stock with a sell rating, six have given a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $249.73.

ResMed Stock Performance

Shares of RMD stock traded down $9.89 on Thursday, hitting $213.11. 1,511,659 shares of the stock traded hands, compared to its average volume of 999,180. The company's fifty day moving average is $232.37 and its 200 day moving average is $237.54. ResMed Inc. has a 1-year low of $172.19 and a 1-year high of $263.05. The company has a market capitalization of $31.30 billion, a PE ratio of 25.16, a PEG ratio of 1.53 and a beta of 0.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29.

ResMed (NYSE:RMD - Get Free Report) last issued its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, topping analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. On average, equities research analysts predict that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th were issued a $0.53 dividend. The ex-dividend date was Thursday, February 13th. This represents a $2.12 dividend on an annualized basis and a yield of 0.99%. ResMed's dividend payout ratio is currently 25.03%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.